GE HealthCare Technologies Inc.

Valuation Analysis

About the Company

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, an

GE HealthCare Technologies Inc. Stock at a Glance

GE HealthCare Technologies Inc. (GEHC) is currently trading at $65.18 with a market capitalization of $29.6B. The trailing P/E ratio stands at 15.63x, with a forward P/E of 12.16x. The 52-week range spans from $58.75 to $89.77; the current price is 27.4% below the yearly high. Year-over-year revenue growth stands at +7.4%. The net profit margin stands at 9.1%.

💰 Dividend

GE HealthCare Technologies Inc. pays an annual dividend of $0.14 per share, representing a yield of 0.21%. The payout ratio stands at 4.2%.

📊 Analyst Rating

18 analysts rate GE HealthCare Technologies Inc. (GEHC) on consensus: Buy. The average price target is $79.72, implying +22.31% from the current price. Analyst price targets range from $65.00 to $98.00.

GE HealthCare Technologies Inc.: The Investment Case in Detail

GE HealthCare Technologies Inc. (GEHC) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 22.31% upside from current levels — analyst sentiment is firmly constructive. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

What to Watch Next

• The forward P/E of 12.16x is meaningfully below the trailing 15.63x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 22.31% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy GE HealthCare Technologies Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.